Related Experiment Video
Updated: Jun 2, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
[GIST refractory to imatinib treatment].
Yusuke Onozawa1, Masanori Terashima
1Division of Clinical Oncology, Shizuoka Cancer Center.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 14, 2011
Summary
Imatinib improved outcomes for advanced gastro-intestinal stromal tumors (GIST), but resistance is a growing issue. Sunitinib offers an effective treatment option for patients with imatinib-resistant GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Context:
- Gastro-intestinal stromal tumor (GIST) treatment landscape.
- Introduction of imatinib revolutionized GIST therapy.
- Emergence of imatinib resistance as a clinical challenge.
Purpose:
- To review the challenges posed by imatinib resistance in GIST.
- To highlight sunitinib as a treatment for imatinib-refractory GIST.
- To discuss the development of novel targeted therapies.
Summary:
- Imatinib significantly improved outcomes for advanced GIST.
- Resistance mechanisms include KIT/PDGFRα mutations and low drug levels.
- Sunitinib is effective in imatinib-resistant GIST cases.
- New molecular targeted drugs are under development.
Impact:
- Improved therapeutic strategies for GIST patients.
- Understanding of resistance mechanisms in GIST.
- Advancement in the development of next-generation therapies for GIST.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...